mirtazapine and Depression studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

Excerpt	Relevance	Reference
"Mirtazapine and SSRIs are widely prescribed as first-line agents for late-life depression."	9.69	Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. ( Baba, H; Bandou, H; Kato, M; Kinoshita, T; Koshikawa, Y; Naito, M; Takekita, Y, 2023)
" The goal of this study was to investigate the association and causal relationship between mirtazapine treatment of patients with depression and pancreatitis."	9.41	Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review. ( Janković, SM; Kostić, MJ; Milosavljević, MN; Pejčić, AV, 2023)
" Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable."	9.30	Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019)
"To evaluate the efficacy and safety of mirtazapine in Japanese patients with fibromyalgia (FM), a parallel-group, randomized, double-blind, placebo-controlled phase IIa study was conducted at 57 sites between November 2012 and February 2014."	9.22	Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. ( Miki, K; Murakami, M; Oka, H; Onozawa, K; Osada, K; Yoshida, S, 2016)
"Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)."	9.22	Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016)
" (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia."	9.17	Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013)
"To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia."	9.17	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013)
" Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms."	9.11	Open trial of mirtazapine in patients with fibromyalgia. ( Lezanska-Szpera, M; Rybakowski, JK; Samborski, W, 2004)
"The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults."	8.87	Mirtazapine versus other antidepressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011)
"Available data suggest that mirtazapine is a cost-effective alternative to amitriptyline and fluoxetine for the treatment of depression."	8.80	Mirtazapine. A pharmacoeconomic review of its use in depression. ( Foster, RH; Holm, KJ; Jarvis, B, 2000)
"Mirtazapine (MIRT) is a multi-target antidepressant used in treatment of severe depression with promising efficacy, but also with important side effects, mainly sedation and weight gain."	8.12	Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. ( Chaves Filho, AJM; Cunha, NL; De Oliveira, GMF; Gadelha Filho, CVJ; Jucá, PM; Macedo, DS; Oliveira, TQ; Soares, MVR; Vasconcelos, SMM; Viana, GA; Vieira, CFX, 2022)
"24 516 people diagnosed with depression, aged 18-99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine."	8.12	Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records. ( Butler, D; Coupland, C; Hippisley-Cox, J; Hollis, C; Jack, RH; Joseph, RM; Knaggs, RD; Morriss, R, 2022)
"This study sought to determine whether chronic dosing of mirtazapine during cocaine withdrawal reduced depression- and anxiety-like behaviors that characterize cocaine withdrawal in animals."	7.91	Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. ( Barbosa Méndez, S; Salazar-Juárez, A, 2019)
"This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression."	7.83	Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016)
"We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan."	7.79	Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013)
" This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice."	7.79	Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013)
"We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine."	7.75	Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009)
" Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS."	7.75	Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009)
"Two patients, a 61-year-old man and a 79-year-old woman, developed profound hyponatremia (sodium levels, 112 and 113 mEq/L, respectively) 7 and 10 days after commencement of mirtazapine for symptoms of depression."	7.74	Mirtazapine associated with profound hyponatremia: two case reports. ( Cheah, CY; Fegan, PG; Ladhams, B, 2008)
"Mirtazapine is known to often provoke restless legs syndrome (RLS)."	7.74	Factors potentiating the risk of mirtazapine-associated restless legs syndrome. ( Kim, JM; Kim, SW; Park, KH; Shin, IS; Yoon, JS; Youn, T, 2008)
"To evaluate the safety, tolerability and efficacy of mirtazapine in patients with the primary diagnosis of chronic pain and concomitant depression in an open post-marketing surveillance study."	7.73	The effect of mirtazapine in patients with chronic pain and concomitant depression. ( Freynhagen, R; Lipfert, P; Muth-Selbach, U; Stevens, MF; Tölle, TR; von Giesen, HJ; Zacharowski, K, 2006)
"Shortly after initiation of mirtazapine (a noradrenergic and serotonergic antidepressant) treatment in four patients with parkinsonism, the authors observed the appearance of REM sleep behavior disorder (RBD)."	7.72	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. ( D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2003)
"Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital."	7.71	Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001)
"To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."	7.71	Severe serotonin syndrome induced by mirtazapine monotherapy. ( González-Macías, J; Hernández, JL; Infante, J; Ramos, FJ; Rebollo, M, 2002)
"This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment."	7.70	Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000)
"People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant."	6.82	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. ( Anderson, IM; Campbell, J; Chew-Graham, C; Davies, S; Dickens, C; Gilbody, S; Hollingworth, W; Kessler, D; Lewis, G; Macleod, U; Peters, TJ; Tallon, D; Wiles, N, 2016)
"Depression is common in schizophrenia and worsens its course."	6.76	Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011)
" Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events."	6.72	Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006)
"Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated."	6.70	An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction."	6.40	A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997)
"Depression is a very prevalent and complex disease."	5.72	Cell Model of Depression: Reduction of Cell Stress with Mirtazapine. ( Correia, AS; Fraga, S; Teixeira, JP; Vale, N, 2022)
" The goal of this study was to investigate the association and causal relationship between mirtazapine treatment of patients with depression and pancreatitis."	5.41	Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review. ( Janković, SM; Kostić, MJ; Milosavljević, MN; Pejčić, AV, 2023)
"Depression is a common problem in elderly patients and frequently is treated with antidepressants."	5.33	Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006)
"Taurine has been known to be related to certain modifications of the immune system."	5.32	Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003)
"This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine."	5.30	The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019)
" Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable."	5.30	Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019)
" Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication."	5.30	A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes ( Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N, 2019)
"To evaluate the efficacy and safety of mirtazapine in Japanese patients with fibromyalgia (FM), a parallel-group, randomized, double-blind, placebo-controlled phase IIa study was conducted at 57 sites between November 2012 and February 2014."	5.22	Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. ( Miki, K; Murakami, M; Oka, H; Onozawa, K; Osada, K; Yoshida, S, 2016)
"Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)."	5.22	Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016)
" (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia."	5.17	Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013)
"To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia."	5.17	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013)
"Overall, in the short-term treatment, these data suggest that commonly used antidepressants sertraline and mirtazapine should be considered as an alternative treatment for depression in AD patients."	5.12	Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. ( Bai, Y; He, Y; Huang, J; Huang, S; Huang, W; Li, H; Li, Y, 2021)
" Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms."	5.11	Open trial of mirtazapine in patients with fibromyalgia. ( Lezanska-Szpera, M; Rybakowski, JK; Samborski, W, 2004)
" We sought to determine if the APOE epsilon4 allele influences response in geriatric depression to mirtazapine and paroxetine, two frequently prescribed antidepressants."	5.10	The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. ( Kremer, C; Murphy, GM; Rodrigues, H; Schatzberg, AF, 2003)
"We obtained access to IPD from seven placebo-controlled trials comparing bupropion, duloxetine, escitalopram, mirtazapine, paroxetine or venlafaxine with placebo in the acute phase treatment of major depression (total n = 2803)."	5.01	Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. ( Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S, 2019)
"Limited evidence suggests that for certain elderly patients, mirtazapine may be preferable to sertraline for treatment of depression."	4.89	Sertraline and mirtazapine as geriatric antidepressants. ( Bhogle, M; Holland, J, 2013)
"The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults."	4.87	Mirtazapine versus other antidepressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011)
"Available data suggest that mirtazapine is a cost-effective alternative to amitriptyline and fluoxetine for the treatment of depression."	4.80	Mirtazapine. A pharmacoeconomic review of its use in depression. ( Foster, RH; Holm, KJ; Jarvis, B, 2000)
"Mirtazapine (MIRT) is a multi-target antidepressant used in treatment of severe depression with promising efficacy, but also with important side effects, mainly sedation and weight gain."	4.12	Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. ( Chaves Filho, AJM; Cunha, NL; De Oliveira, GMF; Gadelha Filho, CVJ; Jucá, PM; Macedo, DS; Oliveira, TQ; Soares, MVR; Vasconcelos, SMM; Viana, GA; Vieira, CFX, 2022)
"24 516 people diagnosed with depression, aged 18-99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine."	4.12	Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records. ( Butler, D; Coupland, C; Hippisley-Cox, J; Hollis, C; Jack, RH; Joseph, RM; Knaggs, RD; Morriss, R, 2022)
"In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients."	4.12	Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022)
"This study sought to determine whether chronic dosing of mirtazapine during cocaine withdrawal reduced depression- and anxiety-like behaviors that characterize cocaine withdrawal in animals."	3.91	Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. ( Barbosa Méndez, S; Salazar-Juárez, A, 2019)
"Our patient was a 49-year-old Japanese woman with a history of depression; she was found in an unconscious state after ingesting boric acid (unknown amount), mirtazapine (1950 mg), and sennosides (780 mg)."	3.91	Cardiac arrest induced by the intentional ingestion of boric acid and mirtazapine treated by percutaneous cardiopulmonary bypass: a case report. ( Matsukawa, T; Nagasawa, H; Nakanishi, H; Saito, K; Yanagawa, Y; Yokoyama, K, 2019)
"This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression."	3.83	Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016)
"To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy."	3.81	Use of antidepressants and association with elective termination of pregnancy: population based case-control study. ( Artama, M; Engeland, A; Furu, K; Gissler, M; Haglund, B; Kieler, H; Malm, H; Nørgaard, M; Stephansson, O; Valdimarsdottir, U; Zoega, H, 2015)
" The purpose of our study was to determine if antidepressants improve depression via the NO pathway using an acute depressive rat model induced by L-arginine (AR)."	3.81	Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. ( Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y, 2015)
" Authors report a case of a 65-year old male patient who was treated with venlafaxine-mirtazapine combination for recurrent depression."	3.79	[Antidepressant treatment associated hyponatremia -- case report]. ( Bognár, Z; Gazdag, G; Vonyik, G, 2013)
"We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan."	3.79	Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013)
" This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice."	3.79	Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013)
"Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression."	3.78	Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012)
"The purpose of this study was to elucidate the mechanism underlying the clinical efficacy of mirtazapine-perospirone combination therapy for treatment-resistant depression in a rat model."	3.77	Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. ( Morita, M; Nakayama, K, 2011)
"Mirtazapine is a new antidepressant used in last years, however experience with it during pregnancy is unsatisfactory on the present."	3.76	Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test. ( Hubickova, L; Kostalova, J; Manakova, E; Zemanova, Z, 2010)
"We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine."	3.75	Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009)
" Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS."	3.75	Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009)
"Two patients, a 61-year-old man and a 79-year-old woman, developed profound hyponatremia (sodium levels, 112 and 113 mEq/L, respectively) 7 and 10 days after commencement of mirtazapine for symptoms of depression."	3.74	Mirtazapine associated with profound hyponatremia: two case reports. ( Cheah, CY; Fegan, PG; Ladhams, B, 2008)
"Mirtazapine is known to often provoke restless legs syndrome (RLS)."	3.74	Factors potentiating the risk of mirtazapine-associated restless legs syndrome. ( Kim, JM; Kim, SW; Park, KH; Shin, IS; Yoon, JS; Youn, T, 2008)
"To evaluate the safety, tolerability and efficacy of mirtazapine in patients with the primary diagnosis of chronic pain and concomitant depression in an open post-marketing surveillance study."	3.73	The effect of mirtazapine in patients with chronic pain and concomitant depression. ( Freynhagen, R; Lipfert, P; Muth-Selbach, U; Stevens, MF; Tölle, TR; von Giesen, HJ; Zacharowski, K, 2006)
"Shortly after initiation of mirtazapine (a noradrenergic and serotonergic antidepressant) treatment in four patients with parkinsonism, the authors observed the appearance of REM sleep behavior disorder (RBD)."	3.72	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. ( D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2003)
"Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital."	3.71	Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001)
"To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."	3.71	Severe serotonin syndrome induced by mirtazapine monotherapy. ( González-Macías, J; Hernández, JL; Infante, J; Ramos, FJ; Rebollo, M, 2002)
"This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment."	3.70	Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000)
"In two women with depression a reduction in hot flushes was noticed by serendipity during treatment with mirtazapine 15-30 mg/daily."	3.70	Treatment of hot flushes with mirtazapine: four case reports. ( Berendsen, HH; Schweitzer, DH; Waldinger, MD, 2000)
"One hundred one patients with major depressive disorder were randomized at baseline to receive either mirtazapine or SSRI treatment."	3.11	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. ( Bandou, H; Kato, M; Kinoshita, T; Koshikawa, Y; Naito, M; Nishida, K; Sakai, S; Takekita, Y, 2022)
"People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant."	2.82	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. ( Anderson, IM; Campbell, J; Chew-Graham, C; Davies, S; Dickens, C; Gilbody, S; Hollingworth, W; Kessler, D; Lewis, G; Macleod, U; Peters, TJ; Tallon, D; Wiles, N, 2016)
"Depression is common in schizophrenia and worsens its course."	2.76	Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011)
"Mirtazapine is an established antidepressant with well-documented efficacy demonstrated in controlled clinical trials."	2.74	Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. ( Adomaitiene, V; Danileviciūte, V; Fokas, V; Gumbrevicius, G; Sveikata, A; Sveikatiene, R, 2009)
" Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events."	2.72	Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006)
"Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated."	2.70	An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001)
"Imipramine was more effective against the clusters related to core symptoms of depression: "depression and guilt", "retardation", and "melancholia", respectively."	2.69	Depressed in-patients respond differently to imipramine and mirtazapine. ( Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 1999)
" Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed."	2.69	Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999)
"The latter yielded results on VMS, insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA) and restless leg syndrome (RLS)."	2.61	Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders. ( Aricò, I; Bonanni, E; Bonsignore, M; Caretto, M; Caruso, D; Di Perri, MC; Galletta, S; Lecca, RM; Lombardi, C; Maestri, M; Miccoli, M; Palagini, L; Provini, F; Puligheddu, M; Savarese, M; Silvestri, R; Simoncini, T; Spaggiari, MC, 2019)
"Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit."	2.53	Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. ( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016)
"Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs."	2.47	[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011)
"Mirtazapine is an effective antidepressant with unique and special mechanism of action characterized by high response and remission rates, relatively early onest of action and favourable side-effect profile."	2.45	[Mirtazapine--pharmacologic action and clinical advantages]. ( Purebl, G; Rihmer, Z, 2009)
"Direct costs for treating depression, i."	2.41	[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. ( Häggström, L; Nordling, S; Norinder, A, 2000)
"Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction."	2.40	A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997)
" Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone."	1.91	Treatment-Resistant Depression (TRD): Is the Opioid System Involved? ( Keidan, L; Pick, CG; Schreiber, S, 2023)
"Receiving treatment for depression is increasingly common among young adults."	1.62	Switches and early discontinuations of antidepressant medication in young adults with depression. ( Lähteenvuo, M; Lampela, P; Taipale, H; Tanskanen, A; Tiihonen, J, 2021)
"Pancreatic cancer is the tumour related to higher rates of depression."	1.62	Depression preceding the diagnosis of pancreatic cancer. ( Carvalho, A; Esperto, H; Ferreira, M; Moreira, H, 2021)
"Depression is a psychiatric disorder with higher incidence in women."	1.51	The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior. ( Alvarez Silva, A; Fernández-Guasti, A, 2019)
"When treating depression, we should consider the risks and benefits of combination therapy in individual patients and take measures to minimize the side effects of medicines."	1.51	Combination of mirtazapine and paroxetine: possible clinically demonstrated interaction? ( Červeňová, J, 2019)
"Depression is prevalent in primary biliary cholangitis (PBC) patients."	1.48	The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. ( Almishri, W; Frolkis, AD; Kaplan, GG; Patten, S; Shaheen, AA; Swain, MG; Vallerand, I, 2018)
"Mirtazapine is a widely-used antidepressant with a multimodal mechanism of action."	1.48	Tachyphylaxis to the Sedative Action of Mirtazapine. ( Papazisis, G; Siafis, S; Tzachanis, D, 2018)
"Fluoxetine was the reference treatment option in the medication models."	1.39	Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013)
"Citalopram is a selective serotonin reuptake inhibitor with a favorable cardiac-safety profile."	1.38	Prolonged QTc interval and torsades de pointes induced by citalopram. ( Abuissa, H; Airey, K; Alla, V; Deshmukh, A; Ulveling, K, 2012)
"Mirtazapine is a widely used antidepressant and the aim of this study was to further investigate its antidepressant activity in rats."	1.33	Study of mirtazapine antidepressant effects in rats. ( Cassanelli, A; Gambarana, C; Raone, A; Rauggi, R; Tagliamonte, A, 2005)
"Depression is a common problem in elderly patients and frequently is treated with antidepressants."	1.33	Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006)
"Taurine has been known to be related to certain modifications of the immune system."	1.32	Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003)
"Mirtazapine is a new antidepressant with a tetracyclic chemical structure that is not related to selective serotonin reuptake inhibitors, tricyclic antidepressants, or monoamine oxidase inhibitors."	1.31	Hypertensive urgency induced by an interaction of mirtazapine and clonidine. ( Abo-Zena, RA; Bobek, MB; Dweik, RA, 2000)
" Long-term administration with imipramine or mirtazapine (10 mg/kg, i."	1.31	Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. ( Biggio, G; Dazzi, L; Ladu, S; Pira, L; Rivano, A; Spiga, F; Vacca, G, 2002)

Research

Studies (158)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Quality of Life Inventory

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (6.33)	18.2507
2000's	61 (38.61)	29.6817
2010's	66 (41.77)	24.3611
2020's	21 (13.29)	2.80

Authors	Studies
Lampela, P	1
Tanskanen, A	1
Lähteenvuo, M	1
Tiihonen, J	2
Taipale, H	1
Oliveira, TQ	1
Chaves Filho, AJM	1
Jucá, PM	1
Soares, MVR	1
Cunha, NL	1
Vieira, CFX	1
Gadelha Filho, CVJ	1
Viana, GA	1
De Oliveira, GMF	1
Macedo, DS	1
Vasconcelos, SMM	1
Joseph, RM	1
Jack, RH	1
Morriss, R	1
Knaggs, RD	1
Butler, D	1
Hollis, C	1
Hippisley-Cox, J	1
Coupland, C	1
Wu, S	1
Lin, M	1
Rice, T	1
Coffey, BJ	1
Correia, AS	1
Fraga, S	1
Teixeira, JP	1
Vale, N	1
Schwalsberger, K	1
Reininghaus, B	1
Reiter, A	1
Dalkner, N	1
Fleischmann, E	1
Fellendorf, F	1
Platzer, M	1
Reininghaus, EZ	1
Naito, M	2
Kato, M	3
Koshikawa, Y	3
Bandou, H	2
Sakai, S	1
Takekita, Y	3
Nishida, K	1
Kinoshita, T	3
Joshi, A	1
Todd, S	1
Finn, DP	1
McClean, PL	1
Wong-Lin, K	1
Milosavljević, MN	1
Janković, SM	1
Kostić, MJ	1
Pejčić, AV	1
Vita, G	1
Compri, B	1
Matcham, F	1
Barbui, C	2
Ostuzzi, G	1
Ishtiak-Ahmed, K	1
Christensen, KS	1
Gasse, C	1
Schreiber, S	2
Keidan, L	1
Pick, CG	2
Ogata, H	1
Higasa, K	1
Kageyama, Y	1
Tahara, H	1
Shimamoto, A	1
Nonen, S	1
Kato, T	1
Baba, H	1
Silvestri, R	1
Aricò, I	1
Bonanni, E	1
Bonsignore, M	1
Caretto, M	1
Caruso, D	1
Di Perri, MC	1
Galletta, S	1
Lecca, RM	1
Lombardi, C	1
Maestri, M	1
Miccoli, M	1
Palagini, L	1
Provini, F	1
Puligheddu, M	1
Savarese, M	1
Spaggiari, MC	1
Simoncini, T	1
Alvarez Silva, A	1
Fernández-Guasti, A	1
Economos, G	1
Lovell, N	1
Johnston, A	1
Higginson, IJ	1
Matsuda, Y	1
Furukawa, Y	1
Yamazaki, R	1
Inamura, K	1
Kito, S	1
Nunomura, A	1
Shigeta, M	1
Červeňová, J	1
Kaneko, Y	1
Mouri, T	1
Seto, Y	1
Nishioka, N	1
Yoshimura, A	1
Yamamoto, C	1
Harita, S	1
Chihara, Y	1
Tamiya, N	1
Yamada, T	1
Uchino, J	1
Takayama, K	1
Ferreira, M	1
Moreira, H	1
Esperto, H	1
Carvalho, A	1
He, Y	1
Li, H	1
Huang, J	1
Huang, S	1
Bai, Y	1
Li, Y	1
Huang, W	1
Buschkamp, JA	1
Frohn, C	1
Juckel, G	1
Leucht, S	1
Fennema, H	1
Engel, RR	1
Kaspers-Janssen, M	1
Szegedi, A	1
Jha, MK	1
Wakhlu, S	1
Dronamraju, N	1
Minhajuddin, A	1
Greer, TL	1
Trivedi, MH	2
Shaheen, AA	1
Kaplan, GG	1
Almishri, W	1
Vallerand, I	1
Frolkis, AD	1
Patten, S	1
Swain, MG	1
Papazisis, G	1
Siafis, S	1
Tzachanis, D	1
De La Garza, N	1
Rush, AJ	1
Killian, MO	1
Grannemann, BD	1
Carmody, TJ	1
Akama, F	1
Mikami, K	1
Watanabe, N	2
Kimoto, K	1
Yamamoto, K	1
Matsumoto, H	2
Simon, GE	1
Noma, H	1
Furukawa, TA	2
Maruo, K	1
Imai, H	1
Shinohara, K	1
Tanaka, S	1
Ikeda, K	1
Yamawaki, S	1
Cipriani, A	2
Mavridis, D	1
White, IR	1
Barbosa Méndez, S	1
Salazar-Juárez, A	1
Zuidersma, M	1
Chua, KC	1
Hellier, J	3
Voshaar, RO	1
Banerjee, S	3
Nagasawa, H	1
Nakanishi, H	1
Saito, K	1
Matsukawa, T	1
Yokoyama, K	1
Yanagawa, Y	1
Almeida, OP	1
Duffy, L	1
Bacon, F	1
Clarke, CS	1
Donkor, Y	1
Freemantle, N	1
Gilbody, S	2
Hunter, R	1
Kendrick, T	1
Kessler, D	2
King, M	1
Lanham, P	1
Lewis, G	3
Mangin, D	1
Marston, L	1
Moore, M	1
Nazareth, I	1
Wiles, N	2
Boudreau, DM	1
Arterburn, D	1
Bogart, A	1
Haneuse, S	1
Theis, MK	1
Westbrook, E	1
Simon, G	1
Rogóż, Z	1
Kabziński, M	1
Sadaj, W	1
Rachwalska, P	1
Gądek-Michalska, A	1
Romeo, R	2
Dewey, M	2
Knapp, M	2
Ballard, C	2
Baldwin, R	2
Bentham, P	2
Fox, C	2
Holmes, C	2
Katona, C	2
Lawton, C	2
Lindesay, J	2
Livingston, G	2
McCrae, N	2
Moniz-Cook, E	2
Murray, J	2
Nurock, S	2
Orrell, M	1
O'Brien, J	2
Poppe, M	2
Thomas, A	3
Walwyn, R	2
Wilson, K	2
Burns, A	2
Holland, J	1
Bhogle, M	1
Kjaersgaard, MI	1
Parner, ET	1
Vestergaard, M	1
Sørensen, MJ	1
Olsen, J	1
Christensen, J	1
Bech, BH	1
Pedersen, LH	1
Puzik, A	1
Möller, J	1
Meiss, F	1
Kontny, U	1
Rössler, J	1
Bognár, Z	1
Vonyik, G	1
Gazdag, G	1
Sun, LM	1
Lin, MC	1
Liang, JA	1
Chang, YJ	1
Chang, SN	1
Sung, FC	1
Muo, CH	1
Kao, CH	1
Purslow, C	1
Munzer, A	1
Sack, U	1
Mergl, R	1
Schönherr, J	1
Petersein, C	1
Bartsch, S	1
Kirkby, KC	1
Bauer, K	1
Himmerich, H	1
Künzel, H	1
Paslakis, G	2
Westphal, S	1
Hamann, B	1
Gilles, M	3
Lederbogen, F	3
Deuschle, M	3
Kieler, H	1
Malm, H	1
Artama, M	1
Engeland, A	1
Furu, K	1
Gissler, M	1
Nørgaard, M	1
Stephansson, O	1
Valdimarsdottir, U	1
Zoega, H	1
Haglund, B	1
Tanidir, C	1
Tanidir, IC	1
Tuzcu, V	1
Verster, JC	1
van de Loo, AJ	1
Roth, T	1
Tripathi, P	1
Tomar, LR	1
Goyal, P	1
Singh, P	1
Yoshino, Y	1
Ochi, S	1
Yamazaki, K	1
Nakata, S	1
Abe, M	1
Mori, Y	1
Ueno, S	1
Ohnishi, M	1
Takegawa, R	1
Hirose, T	1
Hattori, Y	1
Shimazu, T	1
Grover, S	1
Avasthi, A	1
Tripathi, A	1
Tanra, AJ	1
Chee, KY	1
He, YL	1
Chiu, HF	1
Kuga, H	1
Lee, MS	1
Chong, MY	1
Udormatn, P	1
Kanba, S	1
Yang, SY	1
Si, TM	1
Sim, K	1
Tan, CH	1
Shen, WW	1
Xiang, YT	1
Sartorius, N	1
Shinfuku, N	1
Komulainen, E	1
Heikkilä, R	1
Meskanen, K	1
Raij, TT	1
Nummenmaa, L	1
Lahti, J	1
Jylhä, P	1
Melartin, T	1
Harmer, CJ	1
Isometsä, E	1
Ekelund, J	1
Duncan, NA	1
Clifford, KM	1
Shvarts, OM	1
Tallon, D	1
Campbell, J	1
Chew-Graham, C	1
Dickens, C	1
Macleod, U	1
Peters, TJ	1
Anderson, IM	1
Hollingworth, W	1
Davies, S	1
Gupta, R	1
Gupta, K	1
Tripathi, AK	1
Bhatia, MS	1
Gupta, LK	1
Arora, S	1
Vohora, D	1
Huang, WL	1
Liao, SC	1
Kuo, TB	1
Chang, LR	1
Chen, TT	1
Chen, IM	1
Yang, CC	1
Thorkelson, G	1
Bielefeldt, K	1
Szigethy, E	1
Miki, K	1
Murakami, M	1
Oka, H	1
Onozawa, K	1
Yoshida, S	1
Osada, K	1
Jiang, SM	1
Jia, L	1
Liu, J	1
Shi, MM	1
Xu, MZ	1
Cornelius, JR	1
Chung, T	1
Douaihy, AB	1
Kirisci, L	1
Glance, J	1
Kmiec, J	1
FitzGerald, D	1
Wesesky, MA	1
Salloum, I	1
Fusar-Poli, P	1
Martinelli, V	1
Politi, P	1
Hobson, R	1
Zimmermann-Viehoff, F	1
Bergander, B	1
Meissner, K	1
Deter, HC	1
Cheah, CY	1
Ladhams, B	1
Fegan, PG	1
Kim, SW	1
Shin, IS	1
Kim, JM	1
Park, KH	1
Youn, T	1
Yoon, JS	1
Famularo, G	1
Gasbarrone, L	1
De Virgilio, A	1
Minisola, G	1
Bertram, L	1
Liss, Y	1
Grözinger, M	1
Sarginson, JE	1
Lazzeroni, LC	1
Ryan, HS	1
Schatzberg, AF	2
Murphy, GM	2
Belkahia, A	1
Hillaire-Buys, D	1
Dereure, O	1
Guillot, B	1
Raison-Peyron, N	1
Rihmer, Z	1
Purebl, G	1
Zeman, M	1
Jirak, R	1
Jachymova, M	1
Vecka, M	1
Tvrzicka, E	1
Zak, A	1
Danileviciūte, V	2
Sveikata, A	2
Adomaitiene, V	2
Gumbrevicius, G	1
Fokas, V	1
Sveikatiene, R	1
Luppa, P	1
Kopf, D	2
Hamann-Weber, B	1
Habermeyer, B	1
Bayer, U	1
Müller-Spahn, F	1
Mischo, M	1
Nigg, C	1
Kiss, A	1
Manakova, E	1
Hubickova, L	1
Kostalova, J	1
Zemanova, Z	1
Tulner, DM	1
Smith, OR	1
Schins, A	1
de Jonge, P	1
Quere, M	1
Delanghe, JR	1
Crijns, HJ	1
den Boer, JA	1
Korf, J	1
Honig, A	1
Terevnikov, V	1
Stenberg, JH	1
Joffe, M	1
Burkin, M	1
Tchoukhine, E	1
Joffe, G	1
Morita, M	1
Nakayama, K	1
Hannon, B	1
Fitzgerald, P	1
Murphy, M	1
Wichniak, A	2
Wierzbicka, A	1
Linden, M	1
Westram, A	1
Omori, IM	1
Nakagawa, A	1
Churchill, R	1
Clark, MS	1
Smith, PO	1
Jamieson, B	1
Mogi, T	1
Yoshino, A	1
Ikemoto, G	1
Nomura, S	1
Deshmukh, A	1
Ulveling, K	1
Alla, V	1
Abuissa, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Combining Medications to Enhance Depression Outcomes[NCT00590863]	Phase 4	665 participants (Actual)	Interventional	2008-03-31	Completed
Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523]		86 participants (Actual)	Interventional	2018-08-29	Completed
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.[NCT02185131]	Phase 2	16 participants (Actual)	Interventional	2013-09-30	Completed
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial[NCT02646449]	Phase 2	11 participants (Actual)	Interventional	2015-06-30	Completed
Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients[NCT01049347]	Phase 3	127 participants (Actual)	Interventional	1997-10-31	Completed
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]	Phase 2	236 participants (Anticipated)	Interventional	2015-12-31	Active, not recruiting
Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488]	Phase 2	52 participants (Actual)	Interventional	2019-03-26	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Quick Inventory of Depressive Symptoms

Intervention	units on a scale (Mean)
Escitalopram + Bupropion SR	0.6
Venlafaxine XR + Mirtazapine	0.4
Escitalopram + Placebo	0.4

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Drinks Per Drinking Day

Intervention	percentage of participants (Number)
Escitalopram + Bupropion SR	46.6
Venlafaxine XR + Mirtazapine	41.8
Escitalopram + Placebo	46.0

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02185131)
Timeframe: 12 Weeks

Level of Depressive Symptoms

Intervention	Drinks per drinking day (Mean)
Mirtazapine	3.5
Placebo	4.4

Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02185131)
Timeframe: 12 Weeks

Drinks Per Drinking Day

Intervention	Units on a scale (Mean)
Mirtazapine	27.6
Placebo	26.1

Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02646449)
Timeframe: 12 Weeks

Level of Depressive Symptoms

Article	Year
Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review. Journal of psychiatric practice, 2023, 01-01, Volume: 29, Issue:1 Topics: Acute Disease; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Female; Humans;	2023
Antidepressants for the treatment of depression in people with cancer. The Cochrane database of systematic reviews, 2023, 03-31, Volume: 3 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Maj	2023
Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders. Maturitas, 2019, Volume: 129 Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Continuous Positive Airway Pressure; Depression	2019
What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:4 Topics: Adrenergic alpha-2 Receptor Antagonists; Antidepressive Agents; Clinical Trials as Topic; Depression	2020
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:8 Topics: Alzheimer Disease; Antidepressive Agents; Cognition; Depression; Humans; Mirtazapine; Network Meta-A	2021
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. Journal of affective disorders, 2019, 05-01, Volume: 250 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disor	2019
Dealing with missing outcome data in meta-analysis. Research synthesis methods, 2020, Volume: 11, Issue:1 Topics: Bias; Data Collection; Data Interpretation, Statistical; Depression; Haloperidol; Humans; Meta-Analy	2020
Sertraline and mirtazapine as geriatric antidepressants. Psychiatria Danubina, 2013, Volume: 25 Suppl 2 Topics: Aged; Antidepressive Agents; Depression; Geriatric Psychiatry; Humans; Mianserin; Mirtazapine; Pract	2013
Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. European journal of pharmacology, 2015, Apr-15, Volume: 753 Topics: Antidepressive Agents, Tricyclic; Automobile Driving; Computer Simulation; Depression; Dose-Response	2015
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. Inflammatory bowel diseases, 2016, Volume: 22, Issue:6 Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion	2016
[Mirtazapine--pharmacologic action and clinical advantages]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2009, Volume: 11, Issue:1 Topics: Adrenergic alpha-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Depress	2009
[Depression]. Praxis, 2010, Mar-03, Volume: 99, Issue:5 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C	2010
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 31, Issue:181 Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl	2011
Mirtazapine versus other antidepressive agents for depression. The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depression; Humans; M	2011
New formulations of existing antidepressants: advantages in the management of depression. CNS drugs, 2004, Volume: 18, Issue:8 Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri	2004
[Suspected depression]. MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34 Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressiv	2006
A risk-benefit assessment of mirtazapine in the treatment of depression. Drug safety, 1997, Volume: 17, Issue:4 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Depressive Disorder,	1997
Mirtazapine--another new class of antidepressant. Drug and therapeutics bulletin, 1999, Volume: 37, Issue:1 Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Depression; Histamine H1 Antagonists	1999
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. Lakartidningen, 2000, Apr-05, Volume: 97, Issue:14 Topics: Adrenergic alpha-Agonists; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive A	2000
Mirtazapine. A pharmacoeconomic review of its use in depression. PharmacoEconomics, 2000, Volume: 17, Issue:5 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Quality	2000

Article	Year
Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. Journal of affective disorders, 2022, 10-01, Volume: 314 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Mirtazapine; Outcome Assessme	2022
Relationship between circulating mitochondrial DNA and microRNA in patients with major depression. Journal of affective disorders, 2023, 10-15, Volume: 339 Topics: Cell-Free Nucleic Acids; Depression; Depressive Disorder, Major; DNA, Mitochondrial; Humans; MicroRN	2023
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. European journal of clinical pharmacology, 2023, Volume: 79, Issue:11 Topics: Adult; Aged; Depression; Humans; Middle Aged; Mirtazapine; Selective Serotonin Reuptake Inhibitors	2023
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. Journal of affective disorders, 2018, Volume: 234 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body	2018
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and anxiety, 2019, Volume: 36, Issue:4 Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio	2019
Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2019, Volume: 27, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depression; Double-Blin	2019
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes Trials, 2019, Jun-03, Volume: 20, Issue:1 Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Meth	2019
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health technology assessment (Winchester, England), 2013, Volume: 17, Issue:7 Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Dementia; Depr	2013
Unstimulated and glucose-stimulated ghrelin in depressed patients and controls. Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Appetite Regulati	2014
A single dose of mirtazapine attenuates neural responses to self-referential processing. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:1 Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Cerebral Cortex; Depression; Emotions; Female;	2016
Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. Trials, 2016, Feb-03, Volume: 17 Topics: Antidepressive Agents, Tricyclic; Clinical Protocols; Depression; Drug Resistance; Humans; Mianserin	2016
Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain, 2016, Volume: 157, Issue:9 Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Fema	2016
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World journal of gastroenterology, 2016, Jun-14, Volume: 22, Issue:22 Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry research, 2016, Aug-30, Volume: 242 Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression;	2016
FKBP5 polymorphisms and antidepressant response in geriatric depression. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2010, Mar-05, Volume: 153B, Issue:2 Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Female; Genetic Variation; Geriatrics;	2010
Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas, Lithuania), 2009, Volume: 45, Issue:10 Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiaz	2009
Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment. Journal of psychiatric research, 2010, Volume: 44, Issue:8 Topics: Adult; Age Factors; Aged; Analysis of Variance; Antidepressive Agents; Case-Control Studies; Cyclohe	2010
Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiology, 2011, Volume: 63, Issue:3 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Inflammation Mediators; M	2011
Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. Human psychopharmacology, 2011, Volume: 26, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Double-	2011
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. The British journal of psychiatry : the journal of mental science, 2013, Volume: 202 Topics: Antidepressive Agents; Caregivers; Cost-Benefit Analysis; Dementia; Depression; Health Care Costs; H	2013
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarke	2013
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biological psychiatry, 2003, Oct-01, Volume: 54, Issue:7 Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Apolipoproteins E; Chromatography, High Pre	2003
Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry, 2004, Volume: 37, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Depression; Drug Administration Schedule; Female; Fibromyalgia;	2004
Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2006, Volume: 31, Issue:4 Topics: Adrenocorticotropic Hormone; Adult; Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Bod	2006
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. Human psychopharmacology, 2006, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Mass Index; Depre	2006
Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology, 2007, Volume: 32, Issue:6 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Drug Therapy, Combination; Female; Humans; Lith	2007
Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry, 1999, Volume: 32, Issue:3 Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Anxiety	1999
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1999, Volume: 10, Issue:1 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder	1999
[Comparative efficacy of remeron (mirtazapine) and amitriptyline in treatment of patients with depression of moderate intensity]. Voenno-meditsinskii zhurnal, 2000, Volume: 321, Issue:10 Topics: Adrenergic alpha-Antagonists; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Hi	2000
An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. Journal of women's health & gender-based medicine, 2001, Volume: 10, Issue:10 Topics: Adult; Antidepressive Agents; Depression; Estradiol; Female; Hormone Replacement Therapy; Humans; Me	2001
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of pain and symptom management, 2002, Volume: 23, Issue:5 Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug;	2002
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of pain and symptom management, 2002, Volume: 23, Issue:5 Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug;	2002
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of pain and symptom management, 2002, Volume: 23, Issue:5 Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug;	2002
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. Journal of pain and symptom management, 2002, Volume: 23, Issue:5 Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug;	2002

Article	Year
Switches and early discontinuations of antidepressant medication in young adults with depression. Journal of affective disorders, 2021, 12-01, Volume: 295 Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Humans; Mirt	2021
Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. Behavioural brain research, 2022, 02-15, Volume: 419 Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Cognitive Dysfunction; Corticosteron	2022
Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records. Evidence-based mental health, 2022, Volume: 25, Issue:4 Topics: Amitriptyline; Antidepressive Agents; Cohort Studies; Depression; Electronic Health Records; Humans;	2022
Case Report: When Time is of the Essence-Benefits of Mirtazapine in an Adolescent with Major Depressive Disorder and Insomnia, Suicidal Thoughts, and Catatonic Features. Journal of child and adolescent psychopharmacology, 2022, Volume: 32, Issue:3 Topics: Adolescent; Depression; Depressive Disorder, Major; Humans; Mirtazapine; Sleep Initiation and Mainte	2022
Cell Model of Depression: Reduction of Cell Stress with Mirtazapine. International journal of molecular sciences, 2022, Apr-29, Volume: 23, Issue:9 Topics: Cell Line, Tumor; Cell Survival; Depression; Humans; Hydrogen Peroxide; Mirtazapine; Oxidative Stres	2022
Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently? Psychiatria Danubina, 2022,Summer, Volume: 34, Issue:2 Topics: Bupropion; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions;	2022
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. BMC medical informatics and decision making, 2022, 10-07, Volume: 22, Issue:1 Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin	2022
Do sociodemographic and clinical factors affect the selection of initial antidepressant treatment for depression in older adults? Results from a nationwide descriptive study in Denmark. Journal of affective disorders, 2023, 08-01, Volume: 334 Topics: Aged; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Denmark; Depression; Escitalopram;	2023
Treatment-Resistant Depression (TRD): Is the Opioid System Involved? International journal of molecular sciences, 2023, Jul-06, Volume: 24, Issue:13 Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fl	2023
The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior. Pharmacology, biochemistry, and behavior, 2019, Volume: 187 Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, Drug; Dru	2019
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Medical hypotheses, 2020, Volume: 136 Topics: Analgesics; Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Disease Models, Animal;	2020
Mirtazapine-induced long QT syndrome in an elderly patient: a case report. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2020, Volume: 20, Issue:4 Topics: Age Factors; Aged, 80 and over; Antidepressive Agents; Depression; Depressive Disorder, Major; Elect	2020
Combination of mirtazapine and paroxetine: possible clinically demonstrated interaction? Casopis lekaru ceskych, 2019,Winter, Volume: 158, Issue:7-8 Topics: Antidepressive Agents; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Humans; Mirtaz	2019
The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. Internal medicine (Tokyo, Japan), 2020, Volume: 59, Issue:13 Topics: Adult; Aged; Antidepressive Agents; Bronchoscopy; Depression; Female; Humans; Lung Neoplasms; Male;	2020
Depression preceding the diagnosis of pancreatic cancer. BMJ case reports, 2021, Feb-04, Volume: 14, Issue:2 Topics: Abdominal Pain; Antidepressive Agents; Depression; Drug Therapy; Fatigue; Female; Humans; Middle Age	2021
Mirtazapine Induces Nightmares in Depressed Patients. Pharmacopsychiatry, 2017, Volume: 50, Issue:4 Topics: Antidepressive Agents, Tricyclic; Depression; Dreams; Humans; Male; Mianserin; Middle Aged; Mirtazap	2017
Translating the HAM-D into the MADRS and vice versa with equipercentile linking. Journal of affective disorders, 2018, 01-15, Volume: 226 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Major; Female; Humans; Mal	2018
The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PloS one, 2018, Volume: 13, Issue:4 Topics: Aged; Antidepressive Agents; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Cohort Studies; D	2018
Tachyphylaxis to the Sedative Action of Mirtazapine. The American journal of case reports, 2018, Apr-07, Volume: 19 Topics: Adult; Antidepressive Agents, Tricyclic; Conscious Sedation; Depression; Dose-Response Relationship,	2018
Efficacy of Mirtazapine on Irritable Bowel Syndrome with Anxiety and Depression: A Case Study. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2018, Volume: 85, Issue:6 Topics: Antidepressive Agents; Anxiety; Depression; Female; Humans; Irritable Bowel Syndrome; Middle Aged; M	2018
Adding mirtazapine to ongoing SNRIs or SSRIs did not improve symptoms of treatment-resistant depression. Annals of internal medicine, 2019, 02-19, Volume: 170, Issue:4 Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Mirtazapine; Primary Health Care; Sele	2019
Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal. Journal of psychopharmacology (Oxford, England), 2019, Volume: 33, Issue:5 Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cocaine; Depression; Disease Models, Anim	2019
Cardiac arrest induced by the intentional ingestion of boric acid and mirtazapine treated by percutaneous cardiopulmonary bypass: a case report. Journal of medical case reports, 2019, May-16, Volume: 13, Issue:1 Topics: Antidepressive Agents; Boric Acids; Cardiopulmonary Bypass; Depression; Disability Evaluation; Drug	2019
The Challenge of Treating Depression in Dementia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2019, Volume: 27, Issue:9 Topics: Dementia; Depression; Humans; Mirtazapine; Sertraline; Technology Assessment, Biomedical	2019
Influence of body mass index on the choice of therapy for depression and follow-up care. Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De	2013
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacological reports : PR, 2012, Volume: 64, Issue:6 Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A	2012
Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PloS one, 2013, Volume: 8, Issue:8 Topics: Abortion, Spontaneous; Adult; Antidepressive Agents; Cyclohexanols; Depression; Duloxetine Hydrochlo	2013
Side effects of interferon therapy in adolescent melanoma. Pediatric hematology and oncology, 2014, Volume: 31, Issue:4 Topics: Adolescent; Adrenergic alpha-Antagonists; Depression; Humans; Immunologic Factors; Interferon-alpha;	2014
[Antidepressant treatment associated hyponatremia -- case report]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2013, Volume: 15, Issue:3 Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyc	2013
Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? Pharmacoepidemiology and drug safety, 2013, Volume: 22, Issue:12 Topics: Adult; Age Factors; Aged; Antidepressive Agents; Case-Control Studies; Chi-Square Distribution; Como	2013
Linking Clostridium difficile infection with depression. Expert review of anti-infective therapy, 2013, Volume: 11, Issue:8 Topics: Antidepressive Agents; Clostridioides difficile; Clostridium Infections; Depression; Fluoxetine; Hum	2013
Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins, 2013, Nov-19, Volume: 5, Issue:11 Topics: Adult; Antidepressive Agents; CD40 Antigens; Citalopram; Cytokines; Depression; Female; Humans; Inte	2013
[Use of psychotropic drugs in patients with chronic pain]. Revue medicale suisse, 2014, Jan-29, Volume: 10, Issue:415 Topics: Chronic Pain; Cortisone; Depression; Guillain-Barre Syndrome; Humans; Mianserin; Middle Aged; Mirtaz	2014
Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG : an international journal of obstetrics and gynaecology, 2015, Volume: 122, Issue:12 Topics: Abortion, Induced; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Stud	2015
Treatment of depression in an adolescent with cardiomyopathy and arrhythmia. Cardiology in the young, 2015, Volume: 25, Issue:7 Topics: Adolescent; Antidepressive Agents, Tricyclic; Anxiety; Cardiomyopathy, Hypertrophic; Depression; Ele	2015
An unusual presentation of dose dependent SIADH secondary to mirtazapine therapy. The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:11 Topics: Aged; Antidepressive Agents; Citalopram; Depression; Dose-Response Relationship, Drug; Humans; Inapp	2015
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. Neuroscience letters, 2015, Jul-10, Volume: 599 Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes	2015
Effect of lipid emulsion during resuscitation of a patient with cardiac arrest after overdose of chlorpromazine and mirtazapine. The American journal of emergency medicine, 2015, Volume: 33, Issue:10 Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cardiopulmonary Resuscitation; Chlorpromazin	2015
Antidepressant Prescription Pattern in the Presence of Medical Co-morbidity: REAP-AD 2013 Study. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, 2015, Volume: 25, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic;	2015
Mirtazapine-Associated Hypertriglyceridemia and Hyperglycemia. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2015, Volume: 30, Issue:11 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Hyperglycemia; Hypertriglyceridemia; Mal	2015
Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. Pharmacology, 2016, Volume: 97, Issue:3-4 Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Depression;	2016
Comparative Evaluation of Partial α2 -Adrenoceptor Agonist and Pure α2 -Adrenoceptor Antagonist on the Behavioural Symptoms of Withdrawal after Chronic Alcohol Administration in Mice. Basic & clinical pharmacology & toxicology, 2016, Volume: 119, Issue:2 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Alcoholism; Animals; Anxiety; Be	2016
The Effects of Antidepressants and Quetiapine on Heart Rate Variability. Pharmacopsychiatry, 2016, Volume: 49, Issue:5 Topics: Adult; Aged; Antidepressive Agents; Anxiety; Depression; Female; Heart Rate; Humans; Linear Models;	2016
Successful antidepressive treatment with mirtazapine following lung transplantation. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Oct-01, Volume: 32, Issue:7 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Lung Transplantation; Male; Mianserin;	2008
[Integrative therapy of a patient with complex psychosomatic complaints]. Forschende Komplementarmedizin (2006), 2008, Volume: 15, Issue:3 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Dyspepsia; Female; Humans; Integrative Medicine;	2008
Mirtazapine associated with profound hyponatremia: two case reports. The American journal of geriatric pharmacotherapy, 2008, Volume: 6, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Aged; Antidepressive Agents, Tricyclic; Depression; Female;	2008
Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Human psychopharmacology, 2008, Volume: 23, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antidepressive Agents, Tricycl	2008
Mirtazapine-associated hyponatremia in an elderly patient. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:6 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Hypertension; Hyponatremia; Mian	2009
Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. Acta dermato-venereologica, 2009, Volume: 89, Issue:3 Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Biopsy; C-Reactive Protein; Depression; Drug Ther	2009
Stevens-Johnson syndrome due to mirtazapine - first case. Allergy, 2009, Volume: 64, Issue:10 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Male; Mianserin; Mirtazapine; Patch Tes	2009
Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro endocrinology letters, 2009, Volume: 30, Issue:3 Topics: Adiponectin; Adult; Aged; Antidepressive Agents; Blood Glucose; Body Mass Index; Chi-Square Distribu	2009
Mania associated with mirtazepine treatment and mixed depression. Pharmacopsychiatry, 2010, Volume: 43, Issue:1 Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Depression; Humans; Male; Mianserin; Middle Aged	2010
Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test. Neuro endocrinology letters, 2010, Volume: 31 Suppl 2 Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents, Tricyclic; Chick Embryo; Depression; Do	2010
Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:3 Topics: Animals; Depression; Disease Models, Animal; Dopamine; Drug Resistance; Drug Synergism; Drug Therapy	2011
Treatment of depression as part of end-of-life care. BMJ case reports, 2008, Volume: 2008 Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Carcinoma, Squamou	2008
What do psychiatrists talk about with their depressed patients parallel to prescribing an antidepressant? International journal of psychiatry in clinical practice, 2011, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Combined Modality Therapy; Depression; Depres	2011
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression. American family physician, 2011, Nov-01, Volume: 84, Issue:9 Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re	2011
Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone. Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:1 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Inappropriate ADH Syndrome; Male; Mianse	2012
Prolonged QTc interval and torsades de pointes induced by citalopram. Texas Heart Institute journal, 2012, Volume: 39, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depre	2012
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies. Neuropharmacology, 2012, Volume: 63, Issue:4 Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agent	2012
Antidepressants and unresponsive episodes in the elderly. BMJ case reports, 2012, Jul-17, Volume: 2012 Topics: Age Factors; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depression; Guidelines as Topic; H	2012
[Mirtazapine versus other antidepressive agents for depression]. Ugeskrift for laeger, 2012, Nov-12, Volume: 174, Issue:46 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D	2012
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2013, Volume: 26, Issue:11 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E	2013
Weight change in depressed nursing home patients on mirtazapine. Journal of the American Geriatrics Society, 2002, Volume: 50, Issue:8 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Homes for the Aged; Humans; Male; Mianse	2002
Neutropenia associated with mirtazapine use: is a drop in the neutrophil count in a symptomatic older adults a cause for concern? Journal of the American Geriatrics Society, 2002, Volume: 50, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Female; Hu	2002
Mirtazapine use in two pregnant women: is it safe? Teratology, 2002, Volume: 66, Issue:5 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Depression; Drug Therapy, Combination; Female; Fol	2002
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behavioural brain research, 2002, Nov-15, Volume: 136, Issue:2 Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Gene	2002
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology, 2003, Jan-14, Volume: 60, Issue:1 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Electroencephalography; Humans; Levodopa; Male;	2003
[Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: case report]. Arquivos de neuro-psiquiatria, 2002, Volume: 60, Issue:4 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Genes, Dominant; Humans; Mianserin; Mirt	2002
Re: Mirtazapine in cancer patients. Journal of pain and symptom management, 2003, Volume: 25, Issue:1 Topics: Antidepressive Agents, Tricyclic; Depression; Female; Humans; Male; Mianserin; Middle Aged; Mirtazap	2003
Mirtazapine: another drug responsible for drug-induced acute pancreatitis? A letter of warning. Pancreas, 2003, Volume: 26, Issue:2 Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Mianserin; Mirta	2003
Mirtazapine in suicidal Huntington's disease. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:3 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Huntington Disease; Mianserin;	2003
Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. Advances in experimental medicine and biology, 2003, Volume: 526 Topics: Adolescent; Adult; Depression; Female; Humans; Lymphocytes; Male; Mianserin; Middle Aged; Mirtazapin	2003
Chairmen's introduction. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2003, Volume: 13 Suppl 3 Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Patient Compliance; Pr	2003
Mirtazapine-induced hyponatraemia. The Medical journal of Australia, 2003, Oct-20, Volume: 179, Issue:8 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic;	2003
[Unclear chronic aches. Often depression plays a part therein]. MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2 Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age	2003
Mirtazapine: not a dual action antidepressant? The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:4 Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Serotonin; Synaptic Tr	2004
Mechanism of action of mirtazapine: dual action or dual effect? The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:4 Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Serotonin; Serotonin S	2004
Study of mirtazapine antidepressant effects in rats. The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:3 Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Admin	2005
Non-lethal mirtazapine overdose with rhabdomyolysis. The Australian and New Zealand journal of psychiatry, 2005, Volume: 39, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Drug Overdose; Humans; Male; Mianserin; Mirtaza	2005
36-Year-old woman with loss of consciousness, fever, and tachycardia. Mayo Clinic proceedings, 2005, Volume: 80, Issue:5 Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Back Pain; Depression; Diagnosis, Diffe	2005
The effect of mirtazapine in patients with chronic pain and concomitant depression. Current medical research and opinion, 2006, Volume: 22, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Chronic Disease; Depre	2006
A suspicious bathtub death in a suicidal patient on mirtazapine. Clinical toxicology (Philadelphia, Pa.), 2006, Volume: 44, Issue:1 Topics: Antidepressive Agents, Tricyclic; Asphyxia; Depression; Diagnosis, Differential; Drowning; Female; F	2006
Recurrent hyponatremia associated with citalopram and mirtazapine. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 48, Issue:4 Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Diagnosis, Di	2006
[Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet]. Medicina (Kaunas, Lithuania), 2006, Volume: 42, Issue:12 Topics: Administration, Oral; Adult; Age Factors; Antidepressive Agents, Tricyclic; Chi-Square Distribution;	2006
Cessation of complex visual hallucinations during treatment with mirtazapine. Pharmacopsychiatry, 2007, Volume: 40, Issue:2 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Hallucinations; Humans; Mianserin; Middl	2007
Mirtazapine for depression and comorbidities in older patients with cancer. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Aged; Antidepressive Agents, Tricyclic; Antiemetics; Comorbidity; Depression; Humans; Mianserin; Mir	2007
Can prefrontal theta cordance differentiate between depression recovery and dissimulation? Neuro endocrinology letters, 2007, Volume: 28, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Fatal Outcome; Female; Humans; Mianserin; Mirta	2007
[Differentiated approach to the therapy of endogenous anxious depression]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2007, Issue:12 Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Carbon Radioisotopes; Depression; Female; Follow-U	2007
Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2007, Volume: 9, Issue:3 Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Case-Control Studies; Cognition	2007
Mirtazapine--a new antidepressant. The Medical letter on drugs and therapeutics, 1996, Dec-20, Volume: 38, Issue:990 Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Histamine H1 Antagonists; Hu	1996
Serotonin syndrome with mirtazapine-fluoxetine combination. International journal of geriatric psychiatry, 1998, Volume: 13, Issue:7 Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Tricyclic; Depression; Drug Interactions;	1998
[Mirtazapin--fast and strong effects]. Fortschritte der Neurologie-Psychiatrie, 1998, Volume: 66, Issue:10 Suppl M Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective	1998
Mirtazapine-induced mania in a case of poststroke depression. The Journal of neuropsychiatry and clinical neurosciences, 1999,Winter, Volume: 11, Issue:1 Topics: Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Cerebrovascular Disorders; Depression; Hum	1999
Clinical pharmacology of mirtazapine: revisited. American family physician, 1999, Sep-15, Volume: 60, Issue:4 Topics: Agranulocytosis; Antidepressive Agents, Tricyclic; Anxiety; Depression; Humans; Mianserin; Mirtazapi	1999
[Mirtazapine--the new standard]. Fortschritte der Neurologie-Psychiatrie, 1999, Volume: 67, Issue:8 Suppl Topics: Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Humans; Mianserin; Mirtazapine	1999
Does mirtazapine enhance serotonergic neurotransmission in depressed patients? Psychopharmacology, 2000, Volume: 148, Issue:3 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Male; Mianserin; Middle Aged; M	2000
Hypertensive urgency induced by an interaction of mirtazapine and clonidine. Pharmacotherapy, 2000, Volume: 20, Issue:4 Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Antihypertens	2000
[Macroglossia and tongue papular injury due to mirtazapine treatment]. Medicina clinica, 2000, Jun-10, Volume: 115, Issue:2 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Macroglossia; Male; Mianserin; Mirtazap	2000
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. European psychiatry : the journal of the Association of European Psychiatrists, 2000, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cost-Be	2000
Treatment of hot flushes with mirtazapine: four case reports. Maturitas, 2000, Oct-31, Volume: 36, Issue:3 Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Hot Flashes; Humans; Mianserin; Middle	2000
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Comorbidity; Depressio	2001
[Interference in the serotoninergic and noradrenergic system. Faster out of depression]. MMW Fortschritte der Medizin, 2001, Nov-01, Volume: 143, Issue:44 Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy	2001
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. Synapse (New York, N.Y.), 2002, Volume: 43, Issue:1 Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Carbolines; Cerebral Cortex	2002
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2002, Volume: 12, Issue:2 Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Depression	2002
Severe serotonin syndrome induced by mirtazapine monotherapy. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:4 Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Male; Mianserin; Mirtazapine; Serotonin	2002
Acute and chronic hypertensive headache and hypertensive encephalopathy. Cephalalgia : an international journal of headache, 2002, Volume: 22, Issue:4 Topics: Acute Disease; Antidepressive Agents; Antihypertensive Agents; Anxiety; Arterioles; Cerebral Arterie	2002

mirtazapine and Depression

Research Excerpts

Research

Studies (158)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Quality of Life Inventory

Quick Inventory of Depressive Symptoms

Drinks Per Drinking Day

Level of Depressive Symptoms

Drinks Per Drinking Day

Level of Depressive Symptoms

Reviews

Trials

Other Studies